Insider Selling: REGENXBIO (NASDAQ:RGNX) Insider Sells $29,476.04 in Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 2,161 shares of REGENXBIO stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the sale, the insider owned 213,009 shares of the company’s stock, valued at $2,905,442.76. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The shares were sold at an average price of $11.04, for a total value of $216,472.32.
• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The stock was sold at an average price of $12.86, for a total value of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The stock was sold at an average price of $11.02, for a total value of $168,705.18.

REGENXBIO Price Performance

REGENXBIO stock traded up $1.55 during trading hours on Monday, hitting $14.83. 3,147,107 shares of the stock traded hands, compared to its average volume of 1,379,095. The firm’s 50 day moving average price is $8.29 and its 200-day moving average price is $9.90. The stock has a market capitalization of $766.71 million, a price-to-earnings ratio of -2.65 and a beta of 0.90. REGENXBIO Inc. has a 1 year low of $5.45 and a 1 year high of $16.19.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. The firm had revenue of $6.39 million during the quarter, compared to analyst estimates of $25.84 million. Research analysts forecast that REGENXBIO Inc. will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of REGENXBIO

A number of institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc increased its position in shares of REGENXBIO by 60.4% during the second quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 1,032 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in REGENXBIO in the 3rd quarter valued at $37,000. Captrust Financial Advisors acquired a new stake in REGENXBIO during the 2nd quarter worth $85,000. Entropy Technologies LP acquired a new stake in REGENXBIO during the 1st quarter worth $87,000. Finally, Prudential Financial Inc. purchased a new stake in shares of REGENXBIO during the second quarter worth $87,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on RGNX. Bank of America reduced their price target on shares of REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Leerink Partners increased their price objective on shares of REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of REGENXBIO in a research report on Wednesday, July 1st. Finally, Morgan Stanley set a $16.00 price objective on shares of REGENXBIO in a research note on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.82.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.